CRYO CELL INTERNATIONAL INC: NYSE American Listing Alert – What Investors Need to Know

For investors in Cryo-Cell International Inc. (NYSE American: CCEL), recent news from the NYSE American exchange signals a critical juncture. The company, a leader in cord blood banking, has received a formal notice regarding its compliance with continued listing standards. This summary cuts through the financial jargon to explain what happened, why it matters, and what comes next for CCEL and its shareholders.

1. What Happened? (The Core Event)

Cryo-Cell International Inc. (CCEL), a pioneer in cord blood banking, received a formal notice from the NYSE American stock exchange on March 9, 2026. This notice informed the company that it no longer meets the exchange's continued listing standards, primarily due to significant financial health concerns. This alert signals potential challenges for the company's future on the exchange.

2. When Did It Happen? (Event Date/Timeline)

Cryo-Cell received the official notice on March 9, 2026. The company then publicly disclosed this critical development through an 8-K filing and press release on March 12, 2026, promptly informing investors.

3. Why Did It Happen? (The Financial Reality)

The NYSE American maintains strict "continued listing standards" (specifically Section 1003(a) of its Company Guide) to ensure public companies remain financially sound and transparent. Cryo-Cell's notice highlights two primary financial deficiencies:

• Significant Stockholders' Deficit: As of November 30, 2025, the company reported a stockholders' deficit of approximately $18.5 million. This means its total liabilities (what it owes) significantly exceeded its total assets (what it owns), a clear sign of financial strain.
• Consecutive Net Losses: Cryo-Cell experienced net losses in two of its three most recent fiscal years. Specifically, the company reported losses of approximately $6.2 million for the fiscal year ending November 30, 2025, and $4.1 million for the fiscal year ending November 30, 2024, following a profit of $1.5 million in 2023. Consistent losses are a significant concern for both exchanges and investors.

These financial indicators are crucial for exchanges to assess a company's stability, signaling potential instability and raising questions about its long-term viability without substantial changes.

4. Financial Impact

While the NYSE American notice itself does not immediately impact Cryo-Cell's current operations or financial statements, it underscores significant underlying financial challenges. The core issues leading to the notice are the reported stockholders' deficit of approximately $18.5 million as of November 30, 2025, and consecutive net losses in two of the three most recent fiscal years (approximately $6.2 million for FY2025 and $4.1 million for FY2024).

These deficiencies and the notice carry several potential financial implications:

• Reduced Access to Capital: The company's ability to raise necessary capital through equity or debt offerings could be significantly impaired, potentially limiting funding for operations, research, and growth initiatives.
• Stock Price Volatility and Liquidity: Uncertainty surrounding the company's compliance status and the risk of delisting can increase stock price volatility. Should delisting occur, it would substantially reduce trading liquidity.
• Increased Costs: The company will incur costs to develop and execute a compliance plan, including potential legal, advisory, and administrative expenses.

5. Why Does This Matter? (Impact & Risks)

This notice serves as a serious warning, though it does not immediately affect the trading of Cryo-Cell's common stock (CCEL), which continues to trade on the NYSE American. However, the underlying financial issues—a substantial stockholders' deficit and recurring losses—signal deeper challenges that could significantly impact the company's operations and future. With a current market capitalization of approximately $45 million, these financial challenges are particularly impactful for a company of Cryo-Cell's size.

Key Risks for Investors:

• Delisting: If Cryo-Cell fails to regain compliance, its stock could be delisted from the NYSE American, potentially moving to an over-the-counter (OTC) market. Delisting can severely reduce liquidity, making it much harder for investors to buy or sell shares, and often leads to a significant drop in stock price.
• Capital Access: Financial instability can hinder the company's ability to raise necessary capital for operations, research & development, or growth initiatives, potentially stifling innovation.
• Reputational Damage: The notice can erode investor confidence and potentially strain relationships with partners and customers, particularly in a sensitive sector like cord blood banking where trust is paramount.
• Operational Strain: Addressing these financial issues may necessitate drastic measures, such as aggressive cost-cutting, which could affect service quality or future offerings.

6. Who Is Affected? (Stakeholders / Impact Assessment)

This situation affects various stakeholders:

• Investors: This notice introduces significant uncertainty and risk. The stock price (currently around $3.20 per share) could experience increased volatility as the market assesses the company's recovery prospects. Your investment is directly exposed to these risks.
• Customers: While a direct service impact is unlikely in the short term, long-term financial instability could raise concerns about the company's ability to maintain its premier cryopreservation services or invest in future technologies.
• Employees: Financial challenges can lead to concerns about job security, potential restructuring, or limitations on career growth within the company.
• Competitors: Other players in the stem cell banking space will closely monitor Cryo-Cell's situation, potentially seeking opportunities or reinforcing their own market positions.

7. What Happens Next? (The Path Forward)

Cryo-Cell faces a critical deadline: it must submit a detailed plan of compliance to the NYSE American by April 8, 2026. This plan must clearly outline how the company intends to resolve its stockholders' deficit and achieve sustained profitability.

Potential Strategies Cryo-Cell Might Pursue Include:

• Cost Reduction: Aggressively cutting operational and administrative expenses.
• Capital Raise: Issuing new equity or debt, which could dilute existing shareholders or increase the company's debt burden.
• Asset Sales: Divesting non-core assets to improve liquidity and reduce liabilities.
• Strategic Partnerships: Collaborating with other entities to share costs, expand market reach, or access new technologies.
• Operational Efficiency Improvements: Streamlining processes and optimizing service delivery to boost profitability.

If the NYSE American accepts the plan, Cryo-Cell may receive an extension, typically up to 18 months from the original notice date (March 9, 2026), to execute its strategy and regain full compliance. However, the company explicitly states there is "no assurance" that its plan will be accepted or that it will successfully regain compliance even with an extension. Failure to do so would likely initiate formal delisting proceedings, moving the stock to an OTC market.

8. What Should Investors/Traders Know? (Key Takeaways for Investors)

For investors, here are the key takeaways:

• Understand the Gravity: This is more than a procedural issue; it directly reflects significant financial distress. The company must demonstrate a credible and executable path to financial health.
• Monitor Key Dates: The April 8, 2026, deadline for the compliance plan is crucial. Subsequent announcements regarding the NYSE American's decision on the plan will be equally important.
• Assess Your Risk: Given the high uncertainty and potential for delisting, investors should carefully evaluate their risk tolerance. This situation carries substantial risk of further capital loss.
• Look for Concrete Actions: Do not solely rely on promises. Look for tangible steps the company is taking to improve its balance sheet and profitability, and how those actions are impacting financial results.
• Consider the Upside (if any): If Cryo-Cell successfully executes a robust plan and regains compliance, it could lead to a recovery in investor confidence and stock price. However, this remains a high-risk, high-reward scenario, and success is not guaranteed.
• Seek Professional Advice: For personalized guidance tailored to your financial situation, consider consulting a qualified financial advisor.